2026-04-29T16:56:12Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/89672024-09-27T19:59:28Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Rivero-Menendez, Olga author Alastruey-Izquierdo, Ana author Mellado, Emilia author Cuenca-Estrella, Manuel author 2016-07-04 Since the first description of an azole-resistant A. fumigatus strain in 1997, there has been an increasing number of papers describing the emergence of azole resistance. Firstly reported in the USA and soon after in Europe, it has now been described worldwide, challenging the management of human aspergillosis. The main mechanism of resistance is the modification of the azole target enzyme: 14-α sterol demethylase, encoded by the cyp51A gene; although recently, other resistance mechanisms have also been implicated. In addition, a shift in the epidemiology has been noted with other Aspergillus species (mostly azole resistant) increasingly being reported as causative agents of human disease. This paper reviews the current situation of Aspergillus azole resistance and its implications in the clinical setting. J Fungi (Basel). 2016 Jul 4;2(3). pii: E21. 10.3390/jof2030021 2309-608X 2309-608X Journal of fungi (Basel, Switzerland) 29376938 http://hdl.handle.net/20.500.12105/8967 Aspergillus fumigatus Aspergillosis Azole drug resistance cyp51A Mutations Triazole Resistance in Aspergillus spp.: A Worldwide Problem?